Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. Issue 1 (7th July 2022)

• Record Type: Journal Article
• Authors: McSweeney, Sean; Bergom, Hannah E; Prizment, Anna; Halabi, Susan; Sharifi, Nima; Ryan, Charles; Hwang, Justin
• Is Part Of: Endocrine oncology. Volume 2:Issue 1(2022)
• Page Start: R51
• Page End: R64
• Publication Date: 2022-07-07
• Subjects: genomics -- prostate cancer -- androgens; Endocrine glands -- Cancer -- Periodicals; 616.9944005
• DOI: 10.1530/EO-22-0058
• Languages: English
• ISSNs: 2634-4793

Abstract

Abstract : The androgen receptor (AR) signaling pathway regulates the progression of prostate cancer (PC). Metastatic castration-resistant prostate cancer (mCRPC) patients generally receive AR-targeted therapies (ART) or androgen-deprivation therapies (ADT) with the initial response; however, resistance is inevitably observed. Prior studies have shown activity and upregulation of a family of androgen production, uptake, and conversion – APUC genes – based on genomic analyses of patient germlines. Genetic variants of some APUC genes, such as the conversion gene, HSD3B1, predict response to second-generation androgen-targeted therapies. Studies have begun to elucidate the overall role of APUC genes, each with unique actionable enzymatic activity, in mCRPC patient outcomes. The current role and knowledge of the genetic and genomic features of APUC genes in advanced prostate cancer and beyond are discussed in this review. These studies inform of how interpreting behavior of APUC genes through genomic tools will impact the treatment of advanced prostate cancer.